Natera, Inc. $NTRA Stock Holdings Lifted by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. boosted its stake in Natera, Inc. (NASDAQ:NTRA) by 142.9% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,098 shares of the medical research company’s stock after buying an additional 646 shares during the period. Geneos Wealth Management Inc.’s holdings in Natera were worth $155,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. IFM Investors Pty Ltd bought a new position in Natera in the 1st quarter valued at about $3,498,000. Intech Investment Management LLC grew its position in Natera by 591.4% in the 1st quarter. Intech Investment Management LLC now owns 85,369 shares of the medical research company’s stock valued at $12,072,000 after buying an additional 73,021 shares in the last quarter. Focus Partners Wealth grew its position in Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after buying an additional 474 shares in the last quarter. Capital Impact Advisors LLC bought a new position in Natera in the 1st quarter valued at about $6,686,000. Finally, Bayforest Capital Ltd grew its position in Natera by 95.3% in the 1st quarter. Bayforest Capital Ltd now owns 2,643 shares of the medical research company’s stock valued at $374,000 after buying an additional 1,290 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Shares of NTRA opened at $175.01 on Wednesday. Natera, Inc. has a one year low of $117.27 and a one year high of $183.00. The company has a 50-day moving average of $155.78 and a two-hundred day moving average of $154.38. The stock has a market cap of $24.02 billion, a price-to-earnings ratio of -91.63 and a beta of 1.68.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same quarter in the previous year, the business earned ($0.30) earnings per share. The business’s quarterly revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. Analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Royal Bank Of Canada set a $268.00 target price on shares of Natera and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Cowen reiterated a “buy” rating on shares of Natera in a research report on Friday, August 8th. Stephens restated an “overweight” rating and set a $183.00 price objective on shares of Natera in a research report on Friday, August 15th. Piper Sandler restated an “overweight” rating and set a $220.00 price objective (up previously from $210.00) on shares of Natera in a research report on Monday, August 11th. Finally, Evercore ISI upgraded shares of Natera to a “strong-buy” rating and set a $170.00 price objective for the company in a research report on Monday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $194.00.

Insider Buying and Selling

In other Natera news, CEO Steven Leonard Chapman sold 6,092 shares of the firm’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $139.81, for a total value of $851,722.52. Following the completion of the transaction, the chief executive officer directly owned 169,400 shares in the company, valued at $23,683,814. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Rowan E. Chapman sold 2,750 shares of the firm’s stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $166.99, for a total transaction of $459,222.50. Following the completion of the transaction, the director owned 6,015 shares of the company’s stock, valued at approximately $1,004,444.85. The trade was a 31.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 56,423 shares of company stock valued at $8,459,656. Company insiders own 5.63% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.